When a cycle fails: what should actually change before the next one

A negative result after a transfer is one of the hardest moments in treatment, and it arrives with a peculiar kind of loneliness: everyone around you wants to say something encouraging, and what you actually need is information.

Here is the honest framing. Most people who eventually have a baby through IVF do not do it on the first attempt — cumulative outcomes across three cycles look very different from first-cycle numbers. A failed cycle is a normal part of a process that works for many people. But that is only true if the next cycle is informed by the last one. Repeating an identical protocol because nobody sat down to look at the data is not persistence; it is just an expensive coin flip.

Ask for the cycle summary in writing

Before any conversation about what to do next, ask your clinic for a written summary of what happened. You are entitled to it, and a clinic that treats international patients should produce it without friction. It should include:

• How many eggs were retrieved, and of those, how many were mature
• How many fertilised, and by what method (conventional IVF or ICSI)
• How many were still developing on day 3, and how many reached blastocyst on day 5 or 6
• The grades given to any embryos frozen or transferred
• If genetic testing was used, the full report, not a one-word verdict
• The endometrial thickness and pattern at the time of transfer
• The protocol and doses, day by day, and any adjustments made mid-cycle

This is not an audit. It is the map. Without it, a plan for the next attempt is guesswork dressed up as expertise.

Where a cycle stops tells you what to change

The useful question is not “why did it fail” but “where did it stop”, because each point suggests different adjustments.

Few eggs retrieved. This points at the stimulation: the protocol type, the starting dose, the timing of the trigger. It may also simply reflect ovarian reserve, in which case the honest conversation is about expectations and about whether a different approach — including donor eggs — belongs on the table.

Eggs retrieved but few mature. Often about trigger timing and the size of follicles at trigger.

Fertilisation failure. May point toward sperm factors or toward the fertilisation method used.

Embryos that stall before blastocyst. The hardest category, and usually about egg and sperm quality rather than anything the lab did wrong. It is also where laboratory conditions genuinely matter, which is one of the reasons lab performance is worth asking about when vetting a clinic.

Good embryo, no implantation. This is where attention turns to the uterus and the lining, and where a specialist has the widest range of options to investigate and treat.

The moment you become the ideal customer

After a failure, you are more willing to try anything. That is exactly when the extras appear.

The clearest recent illustration is intrauterine hCG, injected into the uterus before transfer on the theory that it primes the lining. Small trials had looked encouraging for years. In April 2026, a team at the University of Sydney’s NHMRC Clinical Trials Centre published an individual participant data meta-analysis in Human Reproduction Update — reanalysing raw data from 7 verifiable randomised trials covering 2,244 patients — and found no improvement in live birth, clinical pregnancy, miscarriage or ectopic pregnancy, in any subgroup or dose. The earlier signal did not survive contact with the raw numbers.

That is not an argument against ever trying something new. It is an argument for asking one question about every proposed extra: what does the best available evidence say it does to live birth rates? If the answer is about “implantation potential” in the abstract, or about a study of forty patients, you have learned something.

If you have genetically tested embryos left

Patients who travelled for treatment with PGT-A often come home with embryos labelled mosaic and no clear guidance. A propensity-matched study in the May 2026 issue of Fertility and Sterility compared 434 mosaic-embryo transfers with 868 euploid transfers and found the single label hides very different situations: segmental mosaics reached 49.0% live birth and monosomy mosaics 50.8%, close to the 51.7% for euploid embryos, while trisomy mosaics reached 32.4% with higher first-trimester loss.

Both studies come with limits worth stating: the mosaic analysis is observational and matched rather than randomised, and the hCG meta-analysis could only include trials whose raw data could be verified. Neither replaces a conversation with a genetic counsellor about your specific report.

The three questions for the review appointment

1. What specifically will be different next time, and why?
2. What evidence supports that change?
3. What would make you recommend a different route entirely — or a pause?

A clinic that answers all three plainly is one worth continuing with. If the answer to the first is “the same thing again, but let’s hope”, that is information too.

To see how a plan is rebuilt around your own history, read the patient journey.